Bone Marrow Transplantation (2004) 33, 405–410. doi:10.1038/sj.bmt.1704367 Published online 15 December 2003

Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey

E Jantunen1, T Wiklund2, E Juvonen3, M Putkonen4, T Lehtinen5, O Kuittinen6, K Franssila7, K-O Söderström8, S Leppä2,9, E Elonen3, K Remes4 and T Nousiainen1

  1. 1Department of Medicine, Kuopio University Hospital, Kuopio, Finland
  2. 2Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
  3. 3Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  4. 4Department of Medicine, Turku University Central Hospital, Turku, Finland
  5. 5Department of Oncology, Tampere University Hospital, Tampere, Finland
  6. 6Department of Oncology, Oulu University Hospital, Oulu, Finland
  7. 7Medix Laboratories, Espoo, Finland
  8. 8Department of Pathology, University of Turku, Turku, Finland
  9. 9Molecular Cancer Biology Research Program, Haartman Institute, University of Helsinki, Helsinki, Finland

Correspondence: Dr E Jantunen, Department of Medicine, Kuopio University Hospital, P.O.B. 1777, 70211 Kuopio, Finland. E-mail:

Received 25 June 2003; Accepted 15 September 2003; Published online 15 December 2003.



Limited experience is available on the feasibility and efficacy of high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL). Therefore, a nation-wide survey was conducted in adult patients transplanted for PTCL in Finland during 1990–2001. After histopathology review, 37 patients were identified. The median age was 46 years (16–68) at the time of ASCT. Histology included PTCL not otherwise specified in 14 patients, anaplastic large cell lymphoma (ALCL) in 14 patients, and other in nine patients. Disease status at the time of ASCT was CR/PR1 in 18 patients; CR/PR2 in 14 patients, and other in five patients. HDT consisted of either BEAC (N=22) or BEAM (N=15), supported by blood stem cells in 34 patients (92%). Early transplant-related mortality was 11%. With a median follow-up of 24 months from HDT, 16 patients (43%) have relapsed or progressed. The estimated 5-year overall survival (OS) was 54%. Patients with ALCL had superior OS when compared with other subtypes (85 vs 35%, P=0.007). OS at 5 years was 63% in patients transplanted in CR/PR1 vs 45% in those transplanted in other disease status (P=NS). Prospective studies are needed to define the role of ASCT in this lymphoma type.


peripheral T-cell lymphoma, autologous stem cell transplantation, toxicity, outcome